sellWeak cluster of 210b5-1 plan
Semigran Marc sold $882k of EWTX
Chief Development Officer at Edgewise Therapeutics, Inc.. 29,709 shares at an average of $29.69, traded Dec 24, 2024, filed Dec 27, 2024.
Warning score
31Value
$882k
29,709 shares
Holdings after
6,716
-82% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-24-008599, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 24, 2024 | MOption exercise Common Stock10b5-1 | +29,709 | $8.94 | $266k | 36,425 | Dec 27, 2024 |
| Dec 24, 2024 | SOpen-market sale Common Stock10b5-1 | -27,980 | $29.66 | $830k | 8,445 | Dec 27, 2024 |
| Dec 24, 2024 | SOpen-market sale Common Stock10b5-1 | -1,729 | $30.08 | $52k | 6,716 | Dec 27, 2024 |
| Dec 24, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -29,709 | $0.00 | $0 | 270,291 | Dec 27, 2024 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 33Weak | sell 210b5-1 | EWTX Edgewise Therapeutics, Inc. | Russell Alan J Chief Scientific Officer | $2.7M | 100,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.